Cargando…

Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial

BACKGROUND: The coronavirus disease 2019 (COVID‐19) pandemic has caused a large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non–COVID‐19) demonstrated improvement in pulmonary function in patients ARDS using fibrinolytic therapy. A follow‐up trial using the widely avai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moore, Hunter B., Barrett, Christopher D., Moore, Ernest E., Jhunjhunwala, Rashi, McIntyre, Robert C., Moore, Peter K, Wang, Janice, Hajizadeh, Negin, Talmor, Daniel S., Sauaia, Angela, Yaffe, Michael B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280574/ https://www.ncbi.nlm.nih.gov/pubmed/32838109 http://dx.doi.org/10.1002/rth2.12395

Ejemplares similares

MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study
por: Barrett, Christopher D., et al.
Publicado: (2022)

Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial
por: Barrett, Christopher D., et al.
Publicado: (2022)

Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review
por: Barrett, Christopher D., et al.
Publicado: (2020)

Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?
por: Moore, Hunter B., et al.
Publicado: (2020)

Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis
por: Choudhury, Rashikh, et al.
Publicado: (2020)

Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis
por: Fanikos, John, et al.
Publicado: (2021)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment
por: Barrett, Christopher D., et al.
Publicado: (2020)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
por: Jordan Bruno, Ximena, et al.
Publicado: (2022)

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

COVID-19 Diagnosis and Its Impact on Thrombotic Risk in a Cohort of Patients Simultaneously Hospitalized Due to Acute Respiratory Distress Syndrome
por: Coy-Canguçu, Andréa, et al.
Publicado: (2021)

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex
por: Gierula, Magdalena, et al.
Publicado: (2019)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
por: Driever, Ellen G., et al.
Publicado: (2022)

Thrombotic risk determined by rare and common SERPINA1 variants in a population‐based cohort study
por: Manderstedt, Eric, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Risk of neonatal hypothyroidism in newborns from mothers exposed to CTPA during pregnancy: Ancillary data from a prospective outcome study
por: Righini, Marc, et al.
Publicado: (2022)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism—the Tromsø study
por: Børvik, Trond, et al.
Publicado: (2020)

Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study
por: Nakano, Yoshihisa, et al.
Publicado: (2022)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2017)

Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2019)

The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
por: Bissola, Anna-Lise, et al.
Publicado: (2022)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020)

Donor tobacco smoking is associated with postoperative thrombosis after primary liver transplantation
por: Li, Yanni, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rek1cr3dtf0dge2d1u945jbpqq